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Available online 6 August 2011Anti-drug antibodies are elicited by virtually all therapeutic proteins, and standardized assays are
required for clinical monitoring of patients as well as for comparing antibody response to different
therapeutic proteins in clinical trials. Velaglucerase alfa and imiglucerase are enzyme replacement
therapies for the long-term treatment of type 1 Gaucher disease, a lysosomal storage disease
resulting from an inherited deficiency of the enzyme glucocerebrosidase. We used state-of-the-art
tools to develop a panel of assays for detection and characterization of antibody responses to
velaglucerase alfa and imiglucerase. Highly-sensitive, direct bridging electrochemiluminescence
screening assays were developed using samples from treatment-naïve individuals with type 1
Gaucher disease to set cut points. A mouse anti-glucocerebrosidase monoclonal antibody used as a
calibratorwas shown tohave similar affinity andbindingkinetics for anti-velaglucerase alfa andanti-
imiglucerase antibodies. A quantitative radioimmunoprecipitation assay for IgG antibodies was
developed to eliminate false-positives from the highly sensitive screening assay. Using 59 samples
from treatment-naïve individuals with type 1 Gaucher disease, the confirmatory cut points were
calculated to be 1.42 ng/mL for anti-velaglucerase alfa antibodies and 3.23 ng/mL for anti-
imiglucerase antibodies. Isotype-speciﬁc indirect electrochemiluminescence assays were developed
for IgE, IgA, and IgM subclasses. The IgE subclass assay was shown to be more sensitive than the
conﬁrmatory assay using sheep anti-glucocerebrosidase polyclonal antibody cross-linked with
fragments speciﬁc to human IgE, with cut points for anti-velaglucerase alfa or anti-imiglucerase
antibodies determined to be 0.53 and 0.55 ng/mL, respectively. An assay that detects inhibition
in vitro of velaglucerase alfa and imiglucerase hydrolysis of a synthetic substrate in the presence of
antibodies was developed to test for neutralizing antibodies. Using 52 individual healthy human
donor samples and 35 samples from treatment-naïve individuals with type 1 Gaucher disease, cut
points for the velaglucerase alfa and imiglucerase neutralizing antibody assays were determined to
be 20%, such that a sample with greater than 20% inhibition of enzyme activity in the presence of
antibodies was considered positive for neutralizing antibodies. In conclusion, highly sensitive and
equivalent methods were developed and validated to directly compare antibody response to
velaglucerase alfa and imiglucerase treatments in patientswithGaucher disease, andmay contribute
to future internationally standardized assays for antibodydetection inpatientswithGaucher disease.
© 2011 Elsevier B.V. Open access under CC BY-NC-ND license.Keywords:
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46 M. Séllos-Moura et al. / Journal of Immunological Methods 373 (2011) 45–531. Introduction The bridge electrochemiluminescent (ECL) immunoassay, inAnti-drug antibodies occur with virtually all therapeutic
proteins, although the incidence varies considerably, ranging
from less than 10% of patients to nearly 100% (Schellekens,
2004). Factors pre-disposing to antibody development are a
complex interaction between the therapeutic proteins, the for-
mulation, dose, rate of administration, excipients, and patient-
speciﬁc factors (Patten and Schellekens, 2003), making it very
difﬁcult to predict which individuals will develop antibodies
to therapeutic proteins.
Type 1 Gaucher disease was one of the ﬁrst enzyme de-
ﬁciencies to be treated with a replacement enzyme. Gaucher
disease is a lysosomal storage disorder resulting from deﬁ-
ciency of glucocerebrosidase; the lack of this enzyme leads to
accumulation of glucosylceramide within macrophages, which
in turn leads to spleen, liver, bone, and hematologic abnor-
malities (Goker-Alpan, 2010). Replacement of the deﬁcient
enzyme by infusion of puriﬁed or recombinant human enzyme
is associated with improvement in symptoms (Barton et al.,
1991; Grabowski et al., 1995). Initially, replacement enzyme
was puriﬁed from human placental tissue (Ceredase®, Gen-
zyme Corporation, Cambridge, MA), but was limited by supply,
and subsequently a recombinant protein produced in trans-
formed Chinese hamster ovary cells, imiglucerase (Cerezyme®,
Genzyme Corporation, Cambridge, MA), wasmademore wide-
ly available. Typically, patients receive infusions every 2 weeks,
usually in the long-term if not for the remainder of their lives.
Imiglucerase has been used in this way in several thousand
patients to date, with a consistent rate of elicitation of
antibodies, at approximately 15% (Starzyk et al., 2007).
In 2010, another replacement glucocerebroside, velaglu-
cerasealfa (VPRIV®, ShireHumanGenetic Therapies, Cambridge,
MA) was approved by the Food and Drug Administration
(FDA), European Medicines Agency (EMA), and other regula-
tory agencies for use in patients with type 1 Gaucher disease.
Velaglucerase alfa is produced by gene-activation of human
glucocerebrosidase in a human ﬁbroblast cell line, and contains
the native human enzyme sequence. On X-ray crystallography,
velaglucerase alfa is similar to imiglucerase; however, imiglu-
cerase differs at amino acid position 495 where histidine sub-
stitutes for the natural arginine, and the glycosylation patterns
indicate markedly different mannose structures (Brumshtein
et al., 2010). Given the complex nature of antibody elicitation,
whether these factors inﬂuence the rate of antibody formation
is unknown.
With alternative enzyme replacement therapies for type 1
Gaucher disease available, physicians considering treatment
options will require high-quality data on the development of
antibodies in patients treated with imiglucerase or velaglu-
cerase alfa. We therefore developed and validated a panel of
highly sensitive and equivalent assays for the detection and
characterization of anti-velaglucerase alfa and anti-imiglucerase
antibodies.
2. Materials and methods
2.1. Overview
Identical methods were developed to evaluate patient sera
for anti-velaglucerase alfa and anti-imiglucerase antibodies.which the drug is alternatively labeled with capture or de-
tection functional groups, detected all immunoglobulin sub-
classes and was considered the antibody screening assay. The
radioimmunoprecipitation (RIP) assay was conﬁrmatory for
the presence of IgG antibodies, and the Ig subclass electro-
chemiluminescent immunoassays were conﬁrmatory assays
for thepresence of IgA, IgM, and IgE antibodies.Adiagramof the
testing ﬂowchart is shown in Fig. 1. The antibody screening
assays and IgG assays were calibrated and quantitative, using
human antibody-positive controls. The IgA, IgM, and IgE assays
were semi-quantitative and utilized synthetic positive controls,
since naturally occurring IgA, IgM, or IgE antibodies against
velaglucerase alfa or imiglucerasewere not available. To further
test whether antibodies neutralized enzyme activity in vitro,
assays were also developed to measure inhibition in vitro of
velaglucerase alfa and imiglucerase hydrolysis of the substrate
4-nitrophenyl-β-D-glucopyranoside.
2.2. Materials
The ECL assays were read on a SECTOR™ Imager 2400 (Meso
Scale Discovery, Gaithersburg, MD) using Meso Scale Discovery
Workbench® Software. Streptavidin-coated high bind MA2400
96-microwell plates were also purchased from Meso Scale
Discovery, aswere theSulfo-TAG™NHS-EsterKit for ruthenium-
complex labeling and the read buffer S (4×) for ECL assay. Flat-
bottomed Nunc MaxiSorp ELISA plates were purchased from
Nalge Nunc International (Rochester, NY).
EZ-Link® Sulfo-NHS-LC-Biotinylation Kits and BCA™
Protein Assay Kits were acquired from Pierce (Pierce Protein
Research Products from Thermo Fisher Scientiﬁc, Rockford, IL).
Protein G Sepharose 4 Fast Flow columns and ECL Blocker B
were acquired fromGEHealthcare (Piscataway, NJ). Dulbecco's
Phosphate Buffered Saline solution (DPBS) was obtained from
Invitrogen (Carlsbad, CA). Protease-free bovine serum albumin
(BSA) was obtained from American Bioanalytical (Natick, MA).
Puriﬁed sheep anti-glucocerebrosidase polyclonal anti-
body and mouse anti-glucocerebrosidase monoclonal anti-
body were both prepared by Shire Human Genetic Therapies.
The sheep anti-glucocerebrosidase polyclonal antibody
(G140) was raised in sheep hyperimmunized with velaglu-
cerase alfa and cross-reactive with imiglucerase, and puriﬁed
using Protein G columns (hence was an IgG antibody) and
screened by ELISA. Themouse anti-glucocerebrosidasemono-
clonal antibody (clone number TK9E4-D1-F2-002 “9E4”) was
raised against velaglucerase alfa in BALB/c mice and was
cross-reactive to imiglucerase; as with the polyclonal anti-
body, it was puriﬁed using Protein G columns and screened by
ELISA. The goat anti-mouse IgG, Fc antibody used for the
kinetic study of assay reagents was purchased from MP
Biomedical/Cappel (Solon, OH). Pooled and individual normal
human sera and cynomolgus monkey serum were obtained
from Bioreclamation (Hicksville, NY). Gaucher disease serum
positive for imiglucerase antibody was obtained from a pa-
tient screened for entry into a Shire Human Genetic Therapies
clinical study who was subsequently excluded because base-
line serum samples revealed a pre-existing high titer anti-
body to imiglucerase that cross-reacted with velaglucerase
alfa. Goat-anti-human antibody (IgA, IgM, or IgE speciﬁc) was
obtained from Jackson Immuno Research (IgA) and Chemicon
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Fig. 1. Testing ﬂowchart. 1Positive cut point (CP) in ECL units and ng/mL; 2Report titer; 3Report %inhibition.
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β-D-glucopyranoside was obtained from Acros Organics
(from Thermo Fisher Scientiﬁc, Rockford, IL) and calibrator
p-nitrophenol was obtained fromMP Biomedicals (Irvine, CA).
Velaglucerase alfa was provided by Shire Human Genetic
Therapies, Inc. Imiglucerase was obtained from Genzyme Cor-
poration (Cambridge, MA). Biotin-conjugated velaglucerase
alfa or imiglucerase was prepared using the EZ-Link® Sulfo-
NHS-LC-BiotinylationKit, following themanufacturer's instruc-
tions, and stored in blocking buffer. Ruthenium-complex-
labeled velaglucerase alfa or imiglucerase was prepared using
the MSD Sulfo-TAG™ NHS-Ester Kit, following the manufac-
turer's instructions, and stored in blocking buffer. 125I-velaglu-
cerase alfa and 125I-imiglucerasewere custom labeledbyPerkin
Elmer (Waltham,MA) usingmaterial providedby ShireHuman
Genetic Therapies.
2.3. Methods
2.3.1. Screening assay
A bridging ECL assay was used to provide a very sensitive
screen, while remaining tolerant of the presence of the
therapeutic protein. Themethodwas identical for imiglucerase
antibodies, substituting imiglucerase for velaglucerase alfa
wherever written.
The assays were performed in streptavidin-coated, carbon
surface plates that retain a high degree of biological activity
(Meso Scale Discovery, 2010). Because the plate was pre-
coated, the ﬁrst stepwas addition of 150 μL of blocking buffer B
(2% protease-free BSA, 0.5% ECL Blocker B in 1× DPBS) to each
well, followed by incubation at room temperature for 1 h with
gentle shaking. Thewellswere theneachwashedwith 300 μL of
wash buffer (DPBS and 0.05% Tween-20) and then 25 μL biotin-
labeled velaglucerase alfa (1 μg/mL)diluted in blockingbuffer B
was added to each well. The plate was then incubated at room
temperature for 1 h with shaking, to allow the biotin-labeled
velaglucerase alfa to adhere to the plates. The wells were
washed with 300 μL of wash buffer to remove excess biotin-
labeled velaglucerase alfa. 25 μL of sample or controlwas addedto each well. The plate was incubated at room temperature
for 1 h with shaking, to allow the immobilized biotinylated
velaglucerase alfa to capture anti-velaglucerase alfa antibodies
present in the samples or controls, after which the plate was
washed three times with 300 μL wash buffer to remove un-
bound proteins. After this, 25 μL ruthenium-complex-labeled
velaglucerase alfa (1 μg/mL) was added to each well and the
plate was incubated at room temperature for 1 h with shaking,
allowing for the establishment of binding equilibrium and
formation of a complex with the bound anti-velaglucerase alfa
antibodies. Eachwellwaswashed three timeswith300 μLwash
buffer to remove unbound labeled drug, and 150 μL of read
buffer S (diluted to 1×) was added. The plate was read on the
Sector™MSD 2400 instrument within 5 min of the read buffer
being added. Labeled complexes bound to the bottomsurfaceof
the wells emit light by an electrochemiluminescent process
triggered by the instrument. The concentration of anti-
velaglucerase alfa antibodies in test samples was estimated
by interpolating the unknown's measured ECL signal on the
calibration curve.
Samples and normal human serum, used as a negative
control, were prepared as a 1/20 dilution using dilution buffer
(DPBS, 2% BSA, and 0.05% Tween-20). The mouse anti-
glucocerebrosidase monoclonal antibody with cross-reactivity
to velaglucerase alfa and imiglucerase was used as a calibrator
within each assay plate. Using serial dilutions (in normal
human serum in dilution buffer), ﬁnal concentrations ranged
from 4.0 ng/mL to 250 ng/mL. Human serum from a patient
with Gaucher disease and containing anti-imiglucerase anti-
body cross-reactive with velaglucerase alfa was used as the
positive assay control.
2.3.1.1. Kinetic/afﬁnity study of screening assay reagents. The
afﬁnity of the mouse anti-glucocerebrosidase monoclonal
antibody to various forms of glucocerebrosidase was assessed
using a Biacore™ T100 instrument equipped with Biacore
T100 Control and Evaluation Software Set version 2.0.2. A
goat anti-mouse IgG Fc antibody was immobilized on the
CM5 chips by amine coupling. The dextran layer of the sensor
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NV-(3-dimethylaminopropyl) carbodiimide hydrochloride
and N-hydroxysuccinimide. The goat anti-mouse IgG Fc
antibody diluted in 10 mM sodium acetate buffer (pH 5.0) at
a concentration of 25 μg/mL was then injected at a ﬂow rate of
10 μL/min until a surface of 3000 resonance units (RU) was
obtained. The remaining reactive groups on the surface were
blocked by injecting 70 μL of 1 M ethanolamine (pH 8.5). The
mouse anti-glucocerebrosidase monoclonal antibody was used
as capture antibody at 2 μg/mL in the running buffer (1× HBS-
EP, 10 mMHEPES, 150 mMNaCl, 3 mM EDTA, 0.05% surfactant
P20). It was injected at a ﬂow rate of 60 μL/min with 120 s of
contact time to obtain a target value of 100 RU. Velaglucerase
alfa and imiglucerase, both biotinylated and non-biotinylated
(analytes) were serially diluted in 1× HBS-EP to obtain con-
centrations of 0.31, 0.625, 1.25, 2.5, 5, and 10 nM, and injected
at a ﬂow rate of 50 μL/min with a contact time of 300 s and
a dissociation time of 500–1000 s. After each cycle, the CM5
sensor chipwas regeneratedwith 100 mMphosphoric acid, pH
2.0 at a ﬂow rate of 60 μL/min with a contact time of 120 s. The
sensorgrams were evaluated using Biacore™ T100 Evaluation
Software with local Rmax ﬁtting to a 1:1 binding model.
2.3.2. IgG conﬁrmatory assay (radioimmunoprecipitation assay)
Following the highly sensitive screening stage, a speciﬁc
conﬁrmatory assay was required to eliminate false-positives
from the screening results. The assay used was isotype-
speciﬁc for IgG anti-drug antibody. The method described
was identical for imiglucerase antibodies, substituting imi-
glucerase for velaglucerase alfa wherever written.
The assay was performed in solution phase in microdilu-
tion tubes positioned in an 8×12 tube rack, placed within a
shielded box consisting of either leaded Plexiglas or lead foil.
100 μL of samples and controls was added to each tube,
followed by 20 μL of 125I-velaglucerase alfa working solution.
The working solution of 125I-velaglucerase alfa was adjusted
to 250,000±8000 counts per minute (CPM) per 20 μL using
dilution with RIP binding buffer (20 mM NaPO4 pH 7.0,
100 mM NaCl, 0.05% polyoxyethylene 20-sorbitan monolau-
rate). Each tube was mixed brieﬂy, and incubated at room
temperature for 2 h to allow IgG antibodies present to form
antigen/antibody complexes. After 2 h, 120 μL of each sample
was loaded into a separate Protein G column, assembled in a
VersaPlate manifold connected to a vacuum pump, and incu-
bated at room temperature for 20 min. The columns were
washed ﬁve times with 1 mL of RIP binding buffer per wash.
After the last wash, vacuum strength was increased to the
maximum level for 2 min to remove all RIP binding buffer
from the columns.
To quantify the immune complex, each individual column
was placed in a separate gamma counter tube and counted
using the appropriate settings for 125I for 1 min, and themean,
standard deviation, and percent relative standard deviation
(% RSD) of the replicates for all samples, calibration curve
points, controls and blank were calculated. The radioactive
counts that retained in the mini-columnwere proportional to
the concentration of anti-velaglucerase alfa IgG antibodies
in the test sample. The concentration of anti-velaglucerase alfa
IgG antibodies in test samples was estimated from a cali-
bration curve using the same mouse anti-glucocerebrosidase
monoclonal antibody calibrator discussed above.Serum samples for testing were diluted in RIP binding
buffer, to a minimum dilution of 1/20. The calibration curve
was made by serial dilution of the 100 ng/mL stock of mono-
clonal antibody in 5% pooled normal human serum using
RIP binding buffer to 100, 50, 25, 12.5, 6.25, 3.13, 1.56, and
0 ng/mL. The 0 ng/mL calibration curve point served as the
negative control and RIP binding buffer was used as a blank
on each plate. The sheep anti-glucocerebrosidase polyclonal
antibody in RIP binding buffer with 5% pooled normal human
serum was used as a positive control, at concentrations of
600, 200, and 50 ng/mL.
2.3.3. Isotype conﬁrmatory assays (indirect
electrochemiluminescent immunoassays)
Anti-velaglucerase alfa or anti-imiglucerase antibodies
were analyzed for their Ig subclass using isotype-speciﬁc in-
direct ECL immunoassays to conﬁrm IgE, IgA, and IgManti-drug
antibodies. The method described was identical for imiglucer-
ase antibodies, substituting imiglucerase for velaglucerase alfa
wherever written.
Biotinylated velaglucerase alfa was immobilized on
streptavidin-coated microwell plates, and used to capture
any antibodies present in the samples. Anti-IgE, -IgA, or -IgM
antibodies were detected using ruthenium-complex-tagged
anti-human secondary antibodies against the human IgA,
IgM, or IgE domains.
Since anti-velaglucerase alfa or anti-imiglucerase IgA, IgM,
or IgE antibodies were not available to be used as controls,
human IgA-, IgM-, and IgE-antibody synthetic hybrids were
synthesized by chemically cross-linking puriﬁed human IgA,
IgM, or IgE immunoglobulin to the sheep anti-glucocerebro-
sidase polyclonal antibody previously described. The IgA-,
IgM-, and IgE synthetic human–sheep hybrid control anti-
bodies therefore bound to velaglucerase alfa or imiglucerase
through the sheep antibody domain, and were detected using
ruthenium-complex-tagged anti-human secondary anti-
bodies against the human IgA, IgM, or IgE domains.
The method was identical for the preparation of the IgE,
IgA, and IgM hybrid antibody controls, substituting IgA or IgM
for IgE wherever written. The long spacer arm cross-linker
succinimidyl 6-[3′-2-pyridyldithio-propionamido] hexanoate
(LC-SPDP) technique was used as previously described (Gu
et al., 2003). LC-SPDP produced disulﬁde-containing link-
ages on both the sheep polyclonal and human IgE to yield
pyridylthiol-activated proteins. The IgE was then treated with
a reducing agent to expose sulfhydryl groups, enabling it to
link with the IgG. This human IgE–sheep antibody hybrid
preparation was further characterized by size exclusion
chromatography. For the human IgE–GCB antibody hybrid
only, the hybrid antibody was further afﬁnity puriﬁed by a
velaglucerase alfa-coupled Sepharose 4 Fast Flow column in
order to separate any unlinked human IgE.
Samples as well as positive or negative controls were
assayed on each plate. Firstly, 150 μL of 2% blocker buffer B
was added to each well and the plate was incubated at room
temperature with gentle shaking for 1 h. The wells were then
each washed with 300 μL of wash buffer, and 25 μL of diluted
biotin-labeled velaglucerase alfa was added to each well, and
then the plate incubated further for 1 h at room temperature
with gentle mixing. Each well was washed once with 300 μL
wash buffer to remove unbound biotin-labeled velaglucerase
Table 1
Afﬁnity and binding kinetics of the mouse anti-glucocerebrosidase mono-
clonal antibody to key assay analytes.
Analytes ka (1/Ms) kd (1/s) KD (M)
Velaglucerase alfa 9.2E+05 2.7E−04 3.0E−10
Imiglucerase 2.8E+06 1.0E−04 3.7E−10
Biotinylated velaglucerase alfa 4.0E+05 2.2E−04 5.4E−10
Biotinylated imiglucerase 2.0E+06 9.5E−04 4.8E−10
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well, and the plate incubated at room temperature for 1 h
with gentle mixing, to allow the immobilized velaglucerase
alfa to capture any antibodies present. Each well was washed
three times with 300 μL wash buffer to remove unbound
proteins. Next, 25 μL per well (1 μg/mL) anti-human second-
ary antibodies against the human IgA, IgM, or IgE domain
labeled with rutheniumcomplexwere added, and incubated at
room temperature for 1 h with gentle mixing, resulting in the
formation of an Ig class-speciﬁc complex with any bound anti-
velaglucerase alfa antibodies. Each well was washed three
times with 300 μL of wash buffer to remove unbound labeled
secondary antibody. Then, 150 μL of diluted read buffer “T”was
added to each well, and the plate was read immediately with
the Sector™ MSD 2400 instrument, as described for the
screening assay.
Sampleswere prepared as a1/20dilutionusing 2%Blocker B,
1.5 M NaCl, and 0.05% Tween 20 in PBS. Normal human serum
was used as a negative control, prepared as a 1/20 dilution
in dilution buffer. Three levels of artiﬁcial antibody-positive
controls spanning the dynamic ranges of these assays were
prepared since anti-velaglucerase alfa or anti-imiglucerase IgA,
IgM, or IgE antibodies were not available.
2.3.4. Neutralizing antibody assay
Neutralizing antibodies (NAb) interfere with the biological
activity of the enzyme they bind. This assay was designed to
detect the presence in human serum of NAb that interfere
with velaglucerase alfa or imiglucerase activity in vitro, using
an assay to both detect and quantify antibodies that inhibit
enzyme activity. Themethod is based on a colorimetric activity
assay that measures the ability of velaglucerase alfa and
imiglucerase to hydrolyze the synthetic substrate 4-nitrophe-
nyl-β-D-glucopyranoside to p-nitrophenol and D-glucopyrano-
side. The method described was identical for imiglucerase
antibodies, substituting imiglucerase for velaglucerase alfa
wherever written.
Firstly, diluted serum samples or assay controls were mixed
with an equal volume of 500 ng/mL of velaglucerase alfa (ﬁnal
concentration250 ng/mL) in amicrodilution tube. Themixtures
were then incubated at 37 °C for 30 min with constant shaking.
After incubation of serum/enzyme mixtures, 20 μL of each
sample or assay control was added to the bottom of thewells in
96-well Maxisorp® microtiter plates. 80 μL of 10 mM substrate
solution (10 mM substrate [4-nitrophenyl-β-D-glucopyrano-
side] solution in 20 mM citric acid/40 mM sodium phosphate/
0.1% Triton X-100/2.3 mM taurocholic acid, pH 5.5) was quickly
added to each well. For the enzymatic reaction to occur, the
plate was incubated at 37 °C with gentle shaking for 1 h. After
incubation with substrate, 150 μL of stop solution (0.3 M
glycine/0.2 M sodium carbonate, pH 10.7) was quickly added
to all wells, beginning with the wells for the p-nitrophenol
calibration curve. 100 μL of p-nitrophenol standards (at ﬁnal
concentrations of 160, 80, 40, 20, 10, 5, 2.5 and0 μMaftermixing
100 μL of p-nitrophenol standard with 150 μL of stop solution)
was added to the p-nitrophenol calibration curve wells. The
solutions were mixed for 30 s with a microplate shaker before
reading the plate. Plates were read in a Molecular Devices
SPECTRAmax plate reader using Softmax Pro software. The
enzymatic reaction product (p-nitrophenol) was measured at
the absorbance wavelength of 405 nm. Results of the testsamples were expressed relative to the activity measured in
velaglucerase alfa in the absence of serum sample and reported
as percent inhibition: a sample with N20% inhibition was con-
sidered to be “positive”, and a samplewith≤20% inhibitionwas
considered to be “negative”.
Serumsamples thatwerepositive for anti-velaglucerase alfa
antibody were diluted in NAb sample diluent (20 mM citric
acid/40 mM sodium phosphate/0.1% Triton X-100/1 mg/mL
BSA, pH 5.5), and prepared for NAb quantiﬁcation at 1/10, 1/20,
1/40, and 1/80 ﬁnal dilutions. Serum from normal human
donors was used as a negative control. The puriﬁed sheep anti-
glucocerebrosidase polyclonal antibody was spiked in normal
human serum at 250 μg/mL and used as a positive control. A
patient sample with N30% inhibition was used as a second
positive control.
3. Results
All assays were validated according to FDA and EMA
guidelines (FDA, 2001; EMEA, 2009). To assess assay
repeatability, ﬁve independent assays were performed by a
single analyst. Up to six determinations each of a minimum of
three concentrations were tested in every assay. Intra-assay
precision was determined from up to six determinations per
concentration per day and inter-assay precision was calcu-
lated from the determinations obtained from the ﬁve assays.
Analyst and day effects were established from four indepen-
dent assays performed by two analysts on two different days
(data not shown). Accuracy was determined from the
precision data relative to the mean value of each concentra-
tion. The precision determined at each concentration level did
not exceed 15% of the relative standard deviation (% RSD) as
instructed in the FDA and EMA guidelines.
3.1. Characterization of screening assay reagents
Characterization of the mouse anti-glucocerebrosidase
monoclonal antibody calibrator for the screening assay
showed similar afﬁnity and binding kinetics for velaglucerase
alfa and imiglucerase. Furthermore, there was a negligible
effect on the afﬁnity and binding kinetics when these drugs
were labeled with biotin (Table 1).
3.2. Screening assay
Precision, accuracy, and sensitivity of this assay were
determined according to FDA, EMA, and International Con-
ference on Harmonisation (ICH) guidelines (FDA, 2001; ICH,
2005; EMEA, 2009) and are reported in Table 2. The lowest
Table 2
Screening assay characteristics.
Parameter Speciﬁcation
Velaglucerase alfa Imiglucerase
Precision, % RSD
Intra-assay ≤6.2 ≤6.6
Inter-assay ≤8.5 ≤9.8
Accuracy, % 88.1–112.6 89.2–115.3
Positive cut point, ng/mL 1.67 3.28
Sensitivity (relative to neat serum), ng/mL 33.4 65.6
LOD, ng/mL 5 5
LOQ, ng/mL 15 15
Positive controls Human anti-imiglucerase antibody cross-reactive with
velaglucerase alfa and sheep anti-glucocerebrosidase
polyclonal antibody
Human anti-imiglucerase antibody cross-reactive with
velaglucerase alfa and sheep anti-glucocerebrosidase
polyclonal antibody
Calibrator Mouse anti-glucocerebrosidase monoclonal antibody Mouse anti-glucocerebrosidase monoclonal antibody
Table 3
IgG conﬁrmatory assay (radioimmunoprecipitation assay) characteristics.
Parameter Speciﬁcation
Velaglucerase alfa Imiglucerase
Precision, % RSD
Intra-assay ≤8.7 ≤10.4
Inter-assay ≤12.0 ≤5.1
Accuracy, % 81.4–119.0 87.0–114.0
Positive cut point,
ng/mL
1.42 3.23
Sensitivity
(relative to neat
serum), ng/mL
28.3 64.5
LOD, ng/mL 4 4
LOQ, ng/mL 13 13
Positive controls Human and sheep
anti-glucocerebrosidase
polyclonal antibody
Human and sheep
anti-glucocerebrosidase
polyclonal antibody
Calibrator Mouse
anti-glucocerebrosidase
monoclonal antibody
Mouse
anti-glucocerebrosidase
monoclonal antibody
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(LOQ) were determined according to the following equations,
as recommended by the ICH guidelines (ICH, 2005):
LOD = 3:3 × SD of yinterceptsð Þ½ 
=mean slope of calibration curve
LOQ = 10 × SD of yinterceptsð Þ½ 
=mean slope of calibration curve:
The SD of the y-intercepts and the mean slope were obtained
from anti-glucocerebrosidase antibody calibration curves.
The assay cut point was determined by testing treatment-
naïve patient serum samples and calculating the mean plus
1.645 standard deviation of assay values, where 1.645 is
the 95th percentile of the one-sided normal t-distribution
(Mire-Sluis et al., 2004). A minimum of 67 samples from
individual treatment-naïve patients with Gaucher disease
were tested to set the antibody-positive cut points for the
screening assays for both velaglucerase alfa and imiglucerase.
The test design included at least three analysts testing replicate
samples using a minimum of three different microwell plate
lots over a period of at least 14 days. Two MSD instruments
were used randomly for a minimum of 1170 determinations
for each assay. The assay cut points for anti-velaglucerase alfa
or anti-imiglucerase antibodies were established on the basis
of raw ECL counts and estimated to be 1.67 and 3.28 ng/mL,
respectively (Table 2) by interpolation on a calibration curve.
The assay sensitivity was estimated as the assay cut point
multiplied by the minimum sample dilution factor. The assay
sensitivities were therefore calculated to be 33.4 ng/mL for
anti-velaglucerase alfa antibodies and 65.6 ng/mL for anti-
imiglucerase antibodies.
The LOD and LOQ values were calculated from the anti-
glucocerebrosidase antibody calibration curves. Of note, the
assay cut point values are below or near the instrument limit
of detection. The assay LOD values are greater than the
instrument LOD.
3.3. IgG conﬁrmatory assay (radioimmunoprecipitation assay)
Precision, accuracy, and sensitivity of this assay were
determined as previously described (FDA, 2001; ICH, 2005;EMEA, 2009) and are given in Table 3. The lowest LOD and
lowest LOQ were determined according to the signal-to-noise
method, where a signal-to-noise ratio of 3 is considered
acceptable for estimating the detection limit and a signal-to-
noise ratio of 10 is considered acceptable for estimating the
quantitation limit (EMEA, 2009). Themouse anti-glucocerebro-
sidase monoclonal antibody calibration curve was used to
convert the raw CPM values.
It is widely accepted that the positive cut point for
antibody screening assays should be selected such that a
false-positive rate of 5% is anticipated with 95% conﬁdence
(Mire-Sluis et al., 2004), as described in the previous section.
However, little has been discussed regarding the establish-
ment of an appropriate antibody-positive cut point for
antibody conﬁrmatory assays.
The assay cut point of this conﬁrmatory assay was
established as the mean plus 3 standard deviations of assay
values obtained from treatment-naïve patient serum sam-
ples. A total of 59 samples from individual, treatment-naïve
patients with Gaucher disease were tested to set the
antibody-positive cut point for the radioimmunoprecipitation
conﬁrmatory assays for both velaglucerase alfa and imiglu-
cerase. The assay cut points for anti-velaglucerase alfa and
Table 5
IgM isotype conﬁrmatory assay (indirect electrochemiluminescent immu-
noassays) characteristics.
Parameter Speciﬁcation
Velaglucerase alfa Imiglucerase
Precision, % RSD
Intra-assay ≤6.2 ≤6.5
Inter-assay ≤3.7 ≤3.7
Accuracy, % 94.9–105.6 95.8–103.9
Speciﬁcity μ-Chain Fc μ-Chain Fc
Linearitya, ng/mL 156–2500 156–2500
Cut pointb,
ECL counts
460 460
Positive controlsc Synthetic human–sheep
hybrid antibodyc
Synthetic human–sheep
hybrid antibody
a Based on hybrid control response.
b Positive cut point; ratio of timepoint to baseline must be ≥2.0.
c Synthetic human–sheep hybrid antibody for positive control was cross-
linked as described in the Methods section, by joining a sheep anti-
glucocerebrosidase polyclonal antibody with fragments speciﬁc to human
IgM.
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3.23 ng/mL, respectively (Table 3). The assay sensitivity was
estimated as the assay cut point multiplied by the minimum
sample dilution factor. The assay sensitivity was therefore
estimated to be 28.3 and 64.5 ng/mL for anti-velaglucerase
alfa and anti-imiglucerase antibodies, respectively. This
approach to determine the cut point is therefore supported
by the assay sensitivities estimated for this assay, which are
higher (28.3 ng/mL and 64.5 ng/mL) than the assay sensitiv-
ities of the antibody screening assay (33.4 ng/mL and 65.6 ng/
mL).
It is recognized that assay signal responses can vary over
time and between assay runs (Mire-Sluis et al., 2004),
particularly for assays utilizing radiolabeled reagents, and
therefore the cut point CPM value for this assay may be
adjusted to compensate for radiolabel decay. In order to
normalize inter-assay variability, the cut point CPM can be
adjusted, when necessary, relative to the calibration curve
slope and y-intercept. The least squares line ﬁt to the high-
purity, monoclonal antibody-based calibration curve data,
using well-characterized known concentrations of antibody,
provides a reliable and consistent method for calculating the
uncertainty in assay determinations. This procedure normal-
izes the cut point for inter-assay changes in CPM that may
occur from reagent radiolabel decay, radioautolysis and/or
assay handling variability as well as allowing for changes in
non-speciﬁc binding and for changing assay readouts over
time.
3.4. Isotype conﬁrmatory assays (indirect
electrochemiluminescent immunoassays)
For all the conﬁrmatory assays (IgA, IgM and IgE),
precision and linearity were determined according to
guidelines (FDA, 2001; ICH, 2005; EMEA, 2009) and are
described in Tables 4 and 5. The positive cut points for both
the anti-velaglucerase alfa and anti-imiglucerase IgA and IgM
conﬁrmatory assays (Tables 4 and 5) were determined from
the mean blank (buffer only) result from 59 and 68 assays,
respectively, for both velaglucerase alfa and imiglucerase. TheTable 4
IgA isotype conﬁrmatory assay (indirect electrochemiluminescent immuno-
assay) characteristics.
Parameter Speciﬁcation
Velaglucerase alfa Imiglucerase
Precision, % RSD
Intra-assay ≤3.1 ≤4.7
Inter-assay ≤4.8 ≤8.1
Accuracy, % 93.8–107.4 87.5–109.9
Speciﬁcity α-Chain Fc α-Chain Fc
Linearitya, ng/mL 156–2000 156–2000
Cut pointb,
ECL counts
260 260
Positive controlsc Synthetic human–sheep
hybrid antibodyc
Synthetic human–sheep
hybrid antibody
a Based on hybrid control response.
b Positive cut point; ratio of timepoint to baseline must be ≥2.0.
c Synthetic human–sheep hybrid antibody for positive control was cross-
linked as described in the Methods section, by joining a sheep anti-
glucocerebrosidase polyclonal antibody with fragments speciﬁc to human
IgA.positive cut points were calculated by the signal-to-noise
approach as 10 times the mean blank. Of note, these cal-
culated cut point values were below or near the instrument
limit of detection. A ratio of 2.0, indicating a 2-fold increase in
signal over baseline, has been described in the literature as a
clinically acceptable criterion for an anti-drug antibody-
positive sample (Miller et al., 2001). Patient sera are therefore
deﬁned as positive for anti-velaglucerase alfa or imiglucerase
IgA or IgM antibodies if the signal of the timepoint is greater
than or equal to the respective cut point and if the ratio of the
timepoint signal to the pre-infusion baseline signal is greater
than or equal to 2.0.
For the IgE assays, the assay cut pointwas established as the
mean plus 1.645 standard deviation of assay values obtained
from treatment-naïve patient serum samples as recommended
by Mire-Sluis et al. (2004). A minimum of 67 samples from
individual treatment-naïve patients with Gaucher disease
were tested to set the antibody-positive cut points for the IgE
conﬁrmatory assays for both velaglucerase alfa and imiglu-
cerase using aminimumof 1218 determinations for each assay.
The assay cut points for anti-velaglucerase alfa or anti-
imiglucerase antibodies were determined to be 0.53 and
0.55 ng/mL, respectively (Table 6). The assay sensitivity was
estimated as the assay cut point multiplied by the minimum
sample dilution factor. The assay sensitivity was therefore
calculated to be 10.6 and 11.0 ng/mL for anti-velaglucerase alfa
and anti-imiglucerase antibodies, respectively — higher than
the sensitivity of the screening assays.
3.5. Neutralizing antibody assay
Precision, accuracy, and linearity of the NAb assay were
determined according to established guidelines (FDA, 2001;
ICH, 2005; EMEA, 2009) and are shown in Table 7. The assay
cut point was determined from individual healthy human
donor sera (n=52) and patients with Gaucher disease who
were naïve to enzyme replacement therapy (n=35). The cut
points for the velaglucerase alfa and imiglucerase neutraliz-
ing antibody assays were deﬁned as the mean percent
inhibition plus three standard deviations, resulting in a cut
Table 6
IgE isotype conﬁrmatory assay (indirect electrochemiluminescent immuno-
assays) characteristics.
Parameter Speciﬁcation
Velaglucerase alfa Imiglucerase
Precision, % RSD
Intra-assay ≤6.6 ≤6.6
Inter-assay ≤13.3 ≤14.2
Accuracy, % 87.7–116.1 83.3–121.4
Speciﬁcity ε-Chain ε-Chain
Linearitya, ng/mL 156–10,000 156–10,000
Cut point, ng/mL 0.53 0.55
Sensitivity, ng/mL 10.6 11.0
Positive controlsb Synthetic human–sheep
hybrid antibody
Synthetic human–sheep
hybrid antibody
a Based on hybrid control response.
b Synthetic human–sheep hybrid antibody for positive control was cross-
linked as described in the Methods section, by joining a sheep anti-
glucocerebrosidase polyclonal antibody with fragments speciﬁc to human
IgE.
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velaglucerase alfa and imiglucerase. Therefore, a patient
sample was considered to be negative for inhibitory anti-
bodies if the level of inhibition observed was ≤20.0% and to
be positive if inhibition was N20.0%.
4. Discussion
We used the latest recommendations to develop and
validate a panel of assays for the detection and characterization
of anti-imiglucerase and anti-velaglucerase alfa antibodies. All
anti-velaglucerase alfa and anti-imiglucerase immunoassays
were equivalent, including positive cut-off criteria; the only
differencebetween the assayswas that either velaglucerase alfa
or imiglucerase was used to interrogate the sample.
The screening assays are high throughput, provide in-
creased surface area for detection, allow use of high concen-
tration serum samples with minimum non-speciﬁc binding,
and detect all antibody subclasses. The assays use state-of-the-
art technology and are thus highly sensitive. Both the screening
and conﬁrmatory assays showed an apparent difference in
sensitivity for the two enzymes, with the assays appearing able
to detect lower levels of anti-velaglucerase alfa antibodies than
anti-imiglucerase antibodies. This is perhaps to be expected
since assay sensitivity is determined by the characteristics of
the positive control, which for our assays was the mouseTable 7
Neutralizing antibody assay characteristics.
Parameter Speciﬁcation
Velaglucerase alfa
Precision, % RSD
Intra-assay ≤12.9
Inter-assay ≤6.1
Accuracy, % 89.8–115.4
Linearity, mU/mL 0.3–33.3
Positive cut point, % inhibition N20
Positive controls Human anti-imiglucerase antibody cross-re
velaglucerase alfa and sheep anti-glucocere
polyclonal antibodymonoclonal antibody raised against velaglucerase alfa. There
are known differences between velaglucerase alfa and imiglu-
cerase in terms of amino acid sequence and glycan structure
(Brumshtein et al., 2010), which could account for differences
in sensitivity between the two assays. In practice, this does not
mean that anti-imiglucerase antibodies need to be present at
twice the level of anti-velaglucerase alfa antibodies for
detection, since in our assays, serum positivity was based on
absolute ECLunits so that thedifference in sensitivitywouldnot
affect sample positivity.
The assays reported here were developed in line with
current recommendations for the design and optimization of
immunoassays used in the detection of host antibodies
against biotechnology products (Mire-Sluis et al., 2004).
There are numerous considerations when designing and
developing immunogenicity assays (Mire-Sluis et al., 2004).
Determination of an assay cut point poses challenges in
obtaining a sufﬁcient number of patient samples, especially in
the ﬁeld of rare diseases. A rigorous cut-point assessment
during the validation phase, with a large number of samples
tested and which includes multiple analysts testing over
multiple days, is valuable. In our own experience, a less robust
cut-point was obtained when fewer samples were used.
Testing of a larger number of replicates by several analysts
using different plate lots and instruments yielded a more
robust value.
Electrochemiluminescence-based assays are typically
more sensitive than ELISA-based assays (Mire-Sluis et al.,
2004; Liang et al., 2007), the method used to date in Gaucher
disease (Starzyk et al., 2007), and retrospective comparison
with previous analyses of seroconversion after enzyme
replacement therapy in patients with Gaucher disease must
be interpreted with caution. Nevertheless, having been
developed together, our assays for antibodies to velaglucerase
alfa and imiglucerase should provide enhanced sensitivity for
direct comparison of seroconversion rates between the two
enzymes.
Patients with Gaucher disease treated with enzyme
replacement therapy receive infusions regularly, typically
every other week and, given the chronic nature of the disease,
would be expected to receive lifelong treatment. Conse-
quently, even with relatively low rates of antibody formation
compared with other therapeutic proteins, the risk of
antibody formation remains a concern. The clinical impact
of antibody development in Gaucher disease is uncertain
(Richards et al., 1993; Brady et al., 1997; Ponce et al., 1997;Imiglucerase
≤8.3
≤7.8
86.5–119.3
0.3–33.3
N20
active with
brosidase
Human anti-imiglucerase antibody cross-reactive with
velaglucerase alfa and sheep anti-glucocerebrosidase
polyclonal antibody
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variously reporting both adverse reactions, reduced efﬁcacy,
and no change in efﬁcacy after seroconversion. The parallel
assays developed here will allow direct evaluation and
comparison of antibody responses with velaglucerase alfa
and/or imiglucerase, enabling further study of possible
associations with antibody formation, and may contribute
to future development of international standard assays for
antibody detection in patients with Gaucher disease.
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